Assessing Different Valved Holding Chambers with Facemask for Delivered Mass to Carina with Inhaled Corticosteroid by Pressurized Metered Dose Inhaler

RATIONALE

- To effectively evaluate pressurized metered dose inhaler + Valved Holding Chamber (VHC) delivery systems with a mask, the most appropriate laboratory method is to use a face model that includes soft tissue simulation and an anatomically realistic oro-naso-pharynx airway
- We report a study in which both two types of infant and child mask VHCs were evaluated using the ADAM III anatomical models of an infant and small child
 - n=3 devices per group



AeroChamber Plus* **Flow-Vu*** Anti-Static VHC Trudell Medical International



Free-Breath[†] Spacer

Taian Character Polymer Co., Ltd.

Infant

Child





MD-194A-0818. * trade-marks and registered trade-marks of Trudell Medical International. † trade-marks and registered trade-marks of respective companies. Copyright © Trudell Medical International 201

A. Bracey¹, M. Nagel², J. Suggett² ¹Trudell Medical UK Ltd., Basingstoke, Hampshire, UK. ²Trudell Medical International, London, Ontario, Canada.

METHODS

• Each VHC was evaluated by breathing simulator • ASL5000, IngMar Medical, Pittsburgh, PA

 Tidal breathing – Infant Tidal volume = 50-mL • Inspiratory : Expiratory ratio = 1:3 • Rate/min = 30 cycles

• Tidal breathing – Child • Tidal volume = 155-mL • Inspiratory : Expiratory ratio = 1:2 Rate/min = 25 cycles

 A 2-s delay was introduced before initiating the first respiration cycle to mimic a short coordination delay

• The test chamber with mask was attached to the anatomical model (ADAM III) of a 7 month old infant and a 4 year old child face equipped with modelled airway

 The airway was coupled to the breathing simulator via an electret filter located at the exit to capture drug particles that penetrated as far as the modelled carina

• 5 actuations of Fluticasone Propionate (FP, Flovent 50) were delivered at 30-s intervals

• FP recovered from specific locations in the aerosol pathway was subsequently assayed by HPLC-UV spectrophotometry



RESULTS FP Recovered from VHCs and Models

Following Tidal Breathing

(mean $\mu g \pm SD$ /actuation)

	Infant Pattern		Child Pattern	
	Free-Breath [†]	AeroChamber Plus* Flow-Vu*	Free-Breath [†]	AeroChamber Plus* Flow-Vu*
VHC	40.5 ± 3.7	20.3 ± 1.8	34.2 ± 2.8	17.5 ± 1.6
Facemask	0.0 ± 0.0	1.4 ± 0.2	1.1 ± 0.6	1.4 ± 0.2
Airway	0.0 ± 0.0	0.5 ± 0.1	0.3 ± 0.2	1.1 ± 0.2
Filter at <i>Carina</i>	0.0 ± 0.0	3.0 ± 0.9	5.5 ± 1.8	10.1 ± 1.0



Trudell Medical International^{*}

(br) 2 Ē

CONCLUSIONS



AeroChamber Plus* Flow-Vu* VHC Free-Breath[†] spacer

 Significantly more FP was delivered to filter/carina with the **AeroChamber Plus*** **Flow-Vu*** VHC versus the Free-Breath[†] spacer for both child and infant models • Un-paired t-test, p < 0.001

 As the Free-Breath[†] spacer delivered no medication at all in infant form, this would clearly be a safety concern if replicated in an *in vivo* setting

 Clinicians need to be aware that not all VHCs. are the same and that large differences in delivery may exist when a facemask is present



Excellence By Design